BioPharma Credit (BPCR) has recently made good progress in deploying its cash balance due to drawdowns of second tranches of senior secured loans provided to Sarepta Therapeutics and Global Blood Therapeutics and funding of an additional tranche to Epizyme. Meanwhile, the trust has delivered a solid three-year NAV total return (TR) to end-October 2020 of c 8% per year and its targeted dividend is c0overed in the near term.
24 Nov 2020
BioPharma Credit - Reinvesting proceeds from loan prepayments
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BioPharma Credit - Reinvesting proceeds from loan prepayments
BioPharma Credit PLC USD (BPCR:LON) | 87.6 -0.2 (-0.2%) | Mkt Cap: 1,078m
- Published:
24 Nov 2020 -
Author:
Milosz Papst -
Pages:
7
BioPharma Credit (BPCR) has recently made good progress in deploying its cash balance due to drawdowns of second tranches of senior secured loans provided to Sarepta Therapeutics and Global Blood Therapeutics and funding of an additional tranche to Epizyme. Meanwhile, the trust has delivered a solid three-year NAV total return (TR) to end-October 2020 of c 8% per year and its targeted dividend is c0overed in the near term.